This post was originally published on this site
Regeneron Pharma announced earnings per share of $11.14 on revenue of $2.94B. Analysts polled by Investing.com anticipated EPS of $9.82 on revenue of $2.94B.
Regeneron Pharma shares are up 17.25% from the beginning of the year, still down 3.15% from its 52 week high of $764.59 set on November 1.
Regeneron Pharma’s report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.9B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
